aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company (“aVenture”) is an independent research platform providing information and analysis about startups.
Certain metrics provided by aVenture may seek to assess the risks and opportunities associated with a company, fund, or its representatives (collectively “research”). aVenture seeks to provide this information with objectivity and fairness, and with diligence about its accuracy. Nonetheless, aVenture cannot provide assurance as to the accuracy of the information provided by our research. We strongly advise those using the research platform to seek multiple, independent sources for your research when making financial decisions.
Any links provided to other websites are offered as a matter of convenience and are not intended to imply that aVenture or its authors endorse, sponsor, promote, and/or are affiliated with the owners of or participants in those sites.
The aVenture platform also provides investment listings offered by independent investment advisers in the United States. aVenture is neither a registered investment adviser nor an exempt reporting adviser under the Investment Advisers Act of 1940, and no statements made by aVenture are intended to imply any financial instruments are under the counsel or advice of aVenture or its representatives.
Funds offered on the platform are generally managed by a private investment adviser that, unless stated otherwise, claims exemption from SEC or state registration. Investment funds presented on the platform are only available to investors who meet the requirements of the offering, and solicitations are not made outside those listed jurisdictions.
Additionally, each investment offered on the platform has qualifications for eligibility, including some offered only to Qualified Clients and/or Accredited Investors. Certain funds may be available to non-Qualified or Accredited investors, but only those who become personally known and identifiable to aVenture Investment Company staff, who have had an opportunity to assess the financial capacity and suitability for such an investment, and discuss its risks. Funds, when offered, are only offered following a review of a Private Placement Memorandum (PPM), subscription agreement, and other disclosures.
Investments in startups, venture capital, angel investments, private equity, real estate, stocks, and similar asset classes all involve risks, including: the risk of a decline in the value of your investments, including potentially large declines (suddenly and/or for long periods of time), the potential for illiquidity where part or all of a withdrawal request may not be honored on the date requested (even when a feature of the fund). These risks are heightened during periods of market duress.
Diversification has the possibility of reducing the magnitude of declines (either caused by market/economic factors, or by factors related to the individual company), but does not guarantee these risks have been fully or partially alleviated. Most importantly, past results are not an assurance of future outcomes. While most of these risks are shared and similarly held by other investment asset classes, we recommend investors only consider venture capital investments as part of a broader, diversified portfolio of stocks, bonds, and immediately accessible cash reserves.
From Startups | TechCrunch
By Annie Njanja
April 24, 2024
Madica, an investment program launched by US-based investor Flourish Ventures to back pre-seed startups in Africa, plans to invest in up to 10 ventures by the end of the year, ramping up its funding efforts after closing three initial deals.
Madica disclosed the plans to TechCrunch indicating accelerated investing in the coming year as it eyes up to 30 startups by the end of its three-year program, which started mid last year, after launch late 2022.
Announced today, the program’s initial investees include Kola Market, a B2B platform founded by Marie-Reine Seshie to help SMEs grow their sales and simplify their business operations. Others are GoBEBA, a Kenyan on-demand retailer of household goods founded by Lesley Mbogo and Peter Ndiang’ui, and Newform Foods (formerly Mzansi Meat) a South African cultivated meat startup founded by Brett Thompson and Tasneem Karodia.
More are set to join the program, as Madica explores potential deals in budding markets such as Tunisia, Morocco, Uganda, DRC, Rwanda and Ethiopia. This is in line with its plan to reach startups in diverse sectors and markets, as well as those run by underrepresented and underfunded founders. Madica is further looking beyond fintechs, the most-funded sector in Africa, and is also keen on backing startups by women founders (or where at least one founder is a woman), a demographic that continues to receive measly VC funding.
“I believe that with the number of challenges that exist across the continent, it’s the entrepreneurs who are in those markets that understand the context and have lived experiences around those issues that are best positioned to solve those challenges. The point of the Madica program is to actually prove and show that it’s possible to find founders that are building good businesses but don’t fit the usual homogeneous group,” said Emmanuel Adegboye, Head of Madica.
Madica invests upfront, to a tune of $200,000, once a venture is accepted into the program, which runs for up to 18 months, and also involves tailored hands-on support and mentorship. It has set aside $6 million to invest in scalable tech-enabled business and an equal amount to run the first phase of the program, which has rolling admission. The program does not have standard terms for investment making each deal unique.
“Our programming is both very personalized, but also structured in some ways because founders come into the program at different points. The personalized part of the program is super critical because we want to understand what they need and how we can best support them,” said Adegboye.
“But we also recognize that at every point in time, we’re going to have at least a few companies we’re working with within the program so we have a few parts of the program that are very structured and that cuts across every company within the portfolio,” he said.
Adegboye hopes that as the program catalyzes investments in the pre-seed stage across different ecosystems in Africa, Madica can attract more capital into the continent and eventually serve as a reference for global VCs intending to scale operations in the market.
“Depending on how the program goes, there is a possibility that we will double down on it or open it up to other partners to join us and accelerate this mission.”
View original article on techcrunch.com
Share:
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 25, 2024
Eric Schmidt-backed Augment, a GitHub Copilot rival, launches out of stealth with $252M
AI is supercharging coding — and developers are embracing it. In a recent StackOverflow poll, 44% of software engineers said that they use AI tools as part of their development processes now and 26% plan to soon. Gartner estimates that over half of organizations are currently piloting or have already deployed AI-driven coding assistants, and […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Radical thinks the time has come for solar-powered, high-altitude autonomous aircraft
Though many eyes are on space as orbit develops into a thriving business ecosystem, Radical is keeping things a little closer to the ground — but not too close. Its high-altitude, solar-powered aircraft aim to succeed where Facebook’s infamous Aquila failed by refining the tech and embracing more markets. It’s hard to believe that Facebook’s […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Don't miss our latest news and updates. Subscribe to the newsletter
More from Tech Crunch: